The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 ...
Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential
David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology ...
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other safe stocks to buy for the long term in 2025. The US stock market is often ...
So we wouldn't blame long term Bristol-Myers Squibb Company (NYSE:BMY) shareholders for doubting their decision to hold, with the stock down 14% over a half decade. So let's have a look and see if ...
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Monday, January 13, 2025. The ...
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Monday, January 13, 2025. The company’s presentation and ...
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, January 13, 2025. The company’s presentation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback